You are now leaving the www.LARTRUVO.com website.
Soft tissue sarcoma, or STS, is a cancer that begins in the soft tissues of the body. This can include the muscles, tendons, fat, blood vessels, or other supporting tissue.
There are many different kinds of STS, which are often referred to as subtypes. Some common subtypesSubtypes: Describes the smaller groups that a type of cancer can be divided into, based on features of the cancer cells. are leiomyosarcoma (LMS)Leiomyosarcoma (LMS): A subtype of STS that starts in the smooth muscle cells and is most common in the uterus, abdomen, or pelvis. and liposarcomaLiposarcoma: A subtype of STS that develops in the fat cells of the body., though there are many other types that appear and behave differently.
Approximately 12,000 people in the U.S. will be diagnosed with STS in 2017.
Even though STS is considered a rare cancer, it is important to know that there are resources available to you.
LARTRUVO is a monoclonal antibody, which is different from a traditional chemotherapy.
Monoclonal antibodies are proteins made in the laboratory and can be used to treat some cancers. They bind to substances in the body, including both cancer and healthy cells, and can block signals that tell tumors to grow.
LARTRUVO is given with a chemotherapy called doxorubicinDoxorubicin: A common cancer chemotherapy that also goes under the trade name Adriamycin®.
Adriamycin is a registered trademark of Pharmacia & Upjohn S.P.A., which is an essential part of your treatment plan. Your doctor will start treatment with LARTRUVO and doxorubicin, and may adjust the medicines in your treatment plan over time.
With LARTRUVO and doxorubicin, your treatment unites an innovative therapy with an established cancer medicine.
Tumors can send signals throughout the body that tell cells to grow and divide. LARTRUVO works to block certain types of signals and may help slow down cancer growth.
As a monoclonal antibody, LARTRUVO can bind to healthy cells in addition to cancer cells, which may lead to serious side effects.
LARTRUVO was studied in many different subtypes. Talk to your healthcare team if you have questions regarding your specific subtype.
LARTRUVO has been shown to be effective for adult patients with STS when used with doxorubicin. You are taking LARTRUVO because you and your healthcare team believe it is the right choice for you.
LARTRUVO is given by intravenous (IV) infusionIntravenous (IV) infusion: An infusion of liquid that is delivered through a needle directly into a vein. in a doctor’s office, hospital, or infusion center.
Your treatment will be scheduled in cycles. There are 3 weeks (21 days) in each treatment cycle. You will be given treatment on Days 1 and 8 of each 3-week (21-day) cycle3-week (21-day) cycle: This treatment plan is based on a 21-day calendar, or “cycle.” After 21 days, the first cycle is complete, and your next treatment cycle begins again on Day 1..
Your healthcare team will decide the appropriate length of treatment.
Your treatment plan may include LARTRUVO and doxorubicin for up to 8 cycles of treatment. After the 8th cycle, your healthcare team may decide to continue treatment with LARTRUVO alone. This will depend on the progress of your disease and how your body responds to therapy.
If your medicine changes, it may also affect the side effects you experience.
If your disease progresses at any point during treatment, your doctor will end treatment with LARTRUVO and discuss with you the appropriate next steps on your treatment path.
Each LARTRUVO infusion will last approximately 60 minutes. On the first day of the cycle, your LARTRUVO dose will be given before doxorubicin.
You will receive medications before your LARTRUVO infusion. This will help prepare your body for treatment with LARTRUVO.
Lilly PatientOne: Reimbursement Support
Lilly PatientOne strives to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured. For those who qualify, we can help in the following ways:
For eligibility requirements, or for more information, call 1-866-4PatOne (1-866-472-8663), Monday–Friday, 9 AM–7 PM ET or visit www.LillyPatientOne.com.
If you experience serious side effects at any point during treatment, your doctor may end, delay, or modify your treatment plan.
This is not a full list of side effects.
Talk to your healthcare team if you notice any side effects, including any signs of fever.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/safety/medwatch or call 1-800-FDA-1088.
Feel free to explore these advocacy organizations and educational materials for additional information and resources
LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.
There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.
What is the most important information I should know about LARTRUVO?